Variation of heart-to-mediastinal ratio in123I-mIBG cardiac sympathetic imaging: Its affecting factors and potential corrections

Current Cardiology Reports

Volumn 13, Issue 2, 2011, Pages 132-137

  Chen, Wengen ^a   Cao, Qi ^a   Dilsizian, Vasken ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Cardiac MIBG; Heart failure; Variation

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131;

ANATOMICAL VARIATION; ANTHROPOMETRIC PARAMETERS; ARTICLE; COLLIMATOR; DISEASE ACTIVITY; DRUG MEGADOSE; DRUG UPTAKE; HEART FAILURE; HEART SCINTISCANNING; HEART TO MEDIASTINAL RATIO; HUMAN; ISOTOPE LABELING; NONHUMAN; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; RADIOISOTOPE DIAGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPATHETIC NERVE; SYMPATHETIC TONE;

3-IODOBENZYLGUANIDINE; HEART; HEART FAILURE; HUMANS; MEDIASTINUM; PROGNOSIS; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; RISK ASSESSMENT; SYMPATHETIC NERVOUS SYSTEM; TIME FACTORS;

EID: 79955797835     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0157-y     Document Type: Article

References (25)

1. Nakajo M, Shimabukuro K, Yoshimura H, et al.: Iodine-131 metaiodobenzylguanidine intra- and extravesicular accumulation in the rat heart. J Nucl Med 1986, 27:84-89. (Pubitemid 17023175)
2. Wieland DM, Brown LE, Rogers WL, et al.: Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med 1981, 22:22-31. (Pubitemid 11213140)
3. Kline RC, Swanson DP, Wieland DM, et al.: Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981, 22:129-132. (Pubitemid 11143204)
4. Dilsizian V, Chandrashekhar Y, Narula J: Introduction of New Tests: Low are the mountains, high the expectations. JACC Cardiovasc Imaging 2010, 3:117-119.
5. Flotats A, Carrio I: Cardiac neurotransmission SPECT imaging. J Nucl Cardiol 2004, 11:587-602. (Pubitemid 39341804)
6. Carrio I, Cowie MR, Yamazaki J et al.: Cardiac sympathetic imaging with mBIG in hear failure. JACC Cardiovasc Imaging 2010, 3:92-100.
7. Gerson MC, Craft LL, McGuire N, et al.: Carvedilol improves left ventricular function in heart failure patients with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol 2002, 9:608-615. (Pubitemid 36050207)
8. Verberne HJ, Brewster LM, Somsen GA, et al.: Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008, 29:1147-1159. (Pubitemid 351844881)
9. Verberne HJ, Habraken JB, van Eck-Smit BL, et al.: Variations in 123I-metaiodobenzylguanidine (MIBG) late heart mediastinal ratios in chronic heart failure: a need for standardisation and validation. Eur J Nucl Med Mol Imaging 2008, 35:547-553. This retrospective multicenter study in 290 heart failure patients from six sites of five European countries showed a large variation in acquisition parameters, which contributes to the variation of H/M in patients.
10. Agostini D, Verberne HJ, Burchert W, et al.: I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008, 35:535-546. The paper re-analyzed pooled data on 290 heart failure patients from six sites in five European countries, which confirmed the prognostic value of H/M in heart failure patients.
11. Jacobson AF, Senior R, Cerqueira MD, et al.: Myocardial iodine- 123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010, 55:2212-2221. This multicenter, prospective study on 961 heart failure patients from 96 sites provided validation of the independent prognostic value of H/M in assessing heart failure patients.
12. Inoue Y, Suzuki A, Shirouzu I, et al.: Effect of collimator choice on quantitative assessment of cardiac iodine 123 MIBG uptake. J Nucl Cardiol 2003, 10:623-632. (Pubitemid 38035397)
13. Fletcher AM, Motherwell DW, Small AD, et al.: I-123 MIBG cardiac uptake measurements: limitations of collimator choice and scatter correction in the clinical context. Nucl Med Commun 2010, 31:629-636.
14. Farahati J, Bier D, Scheubeck M, et al.: Effect of specific activity on cardiac uptake of iodine-123-MIBG. J Nucl Med 1997, 38:447-451. (Pubitemid 27376901)
15. Ogita H, Shimonagata T, Fukunami M, et al.: Prognostic significance of cardiac (123)I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart 2001, 86:656-660.
16. Kioka H, Yamada T, Mine T, et al.: Prediction of sudden death in patients with mild-to-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart 2007, 93:1213-1218. (Pubitemid 47492905)
17. Henderson EB, Kahn JK, Corbett JR, et al.: Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988, 78:1192-1199.
18. Nagamachi S, Fujita S, Nishii R, et al.: Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol 2006, 13:34-42. (Pubitemid 43192727)
19. Dae MW, De Marco T, Botvinick EH, et al.: Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts-implications for clinical studies. J Nucl Med 1992, 33:1444-1450.
20. Sisson JC, Wieland DM, Sherman P, et al.: Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. J Nucl Med 1987, 28:1620-1624. (Pubitemid 17158138)
21. Taki J, Nakajima K, Hwang EH, et al.: Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. Eur J Nucl Med Mol Imaging 2000, 27:566-573. (Pubitemid 30262623)
22. Haider N, Baliga RR, Chandrashekhar Y, et al.: Adrenergic excess, hNET1 down-regulation, and compromised mIBG uptake in heart failure poverty in the presence of plenty. JACC Cardiovas Imaging 2010, 3:71-75. This is an excellent editorial viewpoint regarding cardiac mIBG imaging, which also presented data of hNET1 expression in heart failure patients.
23. Backs J, Haunstetter A, Gerber SH, et al.: The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional downregulation. J Mol Cell Cardiol 2001, 33:461-472. (Pubitemid 32539003)
24. Himura Y, Felten SY, Kashiki M, et al.: Cardiac noradrenergic nerve terminal abnormalities in dogs with experimental congestive heart failure. Circulation 1993, 88:1299-1309. (Pubitemid 23264051)
25. Bohm M, La Rosee K, Schwinger RH, et al.: Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 1995, 25:146-153.